ACA CELL Biotech GmbH
Im Breitspiel 6
D-69126 Heidelberg
ADVANTAGES AND PROGRESS BEYOND THE STATE-OF-THE-ART
Straightforward ex vivo manipulation of cells by simple one-time addition of antibody to ACA
The use of strictly autologous source avoids any immune reaction and circumvent the need for immunosuppression
Source of stem cells is easily accessible circulating blood
They do not form teratoma
ACA pluripotent stem cells differentiate in situ to the local cell population
No need to treat the patient with growth factors in order to get the stem cells mobilized into peripheral blood
Virtually endless source of cells
No ethical problems related to the source of cells
OUR TEAM
Dr. Zorica
Becker-Kojić (Ph.D. Chemistry)
CEO, Co-founder and the leading scientists at R&D Centre for Autologous Adult Stem Cell Therapies Heidelberg Germany.
Ergün
Umur
CEO / Co-founder
Dr. Annie
Schott (Ph.D. Biochemistry)
Project leader and protein specialist
Tamara
Appel
Technician
Oksana
Dzekar
Student
John
Greenacre
IT-Consultant
Sabine
Heintzmann
Administration and public relations
